Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Sigma Planning Corp

Sigma Planning Corp lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 61.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,230 shares of the medical equipment provider’s stock after selling 3,620 shares during the quarter. Sigma Planning Corp’s holdings in Zimmer Biomet were worth $271,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Naples Money Management LLC bought a new position in Zimmer Biomet during the fourth quarter worth $35,000. Activest Wealth Management lifted its stake in Zimmer Biomet by 410.4% during the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 275 shares during the last quarter. Peoples Bank KS bought a new position in Zimmer Biomet during the third quarter worth $48,000. Blue Trust Inc. lifted its stake in Zimmer Biomet by 48.4% during the fourth quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock worth $52,000 after purchasing an additional 153 shares during the last quarter. Finally, Quent Capital LLC lifted its stake in Zimmer Biomet by 21.6% during the fourth quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after purchasing an additional 92 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Raymond James raised their price objective on Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. JPMorgan Chase & Co. raised their target price on Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, February 9th. Canaccord Genuity Group reiterated a “hold” rating and issued a $130.00 target price on shares of Zimmer Biomet in a research note on Friday, February 23rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 9th. Finally, TheStreet upgraded Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $139.39.

Insider Buying and Selling

In related news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the transaction, the vice president now directly owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.70% of the stock is owned by corporate insiders.

Zimmer Biomet Price Performance

Shares of ZBH opened at $119.35 on Monday. The firm has a market capitalization of $24.52 billion, a price-to-earnings ratio of 24.41, a price-to-earnings-growth ratio of 2.19 and a beta of 1.01. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $149.25. The stock’s fifty day moving average is $125.98 and its 200-day moving average is $119.67.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. The firm had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. Zimmer Biomet’s revenue was up 6.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.88 earnings per share. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s payout ratio is currently 19.63%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.